Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients w ith Advanced Gastric Cancer

다국어 초록 (Multilingual Abstract)

Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals.Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic feveroccurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.

다국어 초록 (Multilingual Abstract)

Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals.Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5 ∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.

참고문헌 (Reference)

1 "Weekly irinotecan in patients with metastatic gastric cancerfailing cisplatin-based chemotherapy" 34 : 8-13, 2004

2 "Systemic treatment of gastriccancer" 16 : 255-63, 2004

3 "Superiority of oxaliplatin andfluorouracil- leucovorin compared with either therapy alone inpatients with progressive colorectal cancer after irinotecan andfluorouracil- leucovorin: interim results of a Phase III Trial." 21 : 2059-69, 2003

4 "Role of cancer ligand in platinumresistance of human carcinoma cell lines" 53 : 799-805, 1993

5 "Reportingresults of cancer treatment" 47 : 207-14, 1981

6 "Randomized controlled trial offluorouracil plus leucovorin,irinotecan,and oxaliplatin combinationsin patients with previously untreated metastaticcolorectal cancer" 22 : 23-30, 2004

7 "Phase II trial of biweeklyinfusional fluorouracil,folinic acid,and oxaliplatin in patientswith advanced gastric cancer" 22 : 658-63, 2004

8 "Phase II study of weekly oxaliplatin and 24-h infusionof high-dose 5-fluorouracil and folinic acid in the treatment ofadvanced gastric cancer" 91 : 453-8, 2004

9 "Phase II study of oxaliplatin,fluorouracil,andfolinic acid in locally advanced or metastatic gastric cancerpatients" 20 : 4543-48, 2002

10 "Phase II study of oxaliplatin, 5-fluorouracil and leucovorinin previously platinum-treated patients with advanced gastriccancer" 14 : 383-7, 2003

11 "Phase I study of oxaliplatin in patients with advanced cancer" 25 : 299-303, 1990

12 "Pharmacokineticsand safety profile of oxaliplatin" 25 : 13-22, 1998

13 "Oxaliplatin-induced damage of cellularDNA" 58 : 920-7, 2000

14 "Oxaliplatin with biweekly, low dose leucovorin and bolusand continuous infusion 5-fluorouracil (Modified FOLFOX 4)as first-line therapy for patients with metastatic colorectalcancer." 36 : 115-20, 2004

15 "Optimal two-stage designs for phase II clinical trials" 10 : 1-10, 1989

16 "Glimelius B; SBU-group.swedish council of technology assessment in health care. Asystemic overview of chemotherapy effects in gastric cancer" 40 : 309-26, 2001

17 "Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinomacell lines" 54 : 3500-5, 1994

18 "Docetaxel plus cisplatin as second-line therapy in metastaticor recurrent advanced gastric cancer progressing on 5-FUbased regimen" 27 : 477-80, 2004

19 "Cellular determinants of oxaliplatin sensitivity in colon cancercell lines" 39 : 112-9, 2003

20 "Bolus fluorouracil and leucovorin withoxaliplatin as first-line treatment in metastatic colorectalcancer" 20 : 2545-50, 2002

21 "Apoptosis induced by oxaliplatin in human coloncancer HCT15 cell line" 24 : 219-26, 2004

22 "A phase II study of weekly docetaxel as salvagechemotherapy for advanced gastric cancer" 11 : 1263-6, 2000

23 "2001 Annual reportof the Korea central cancer registry: based on registred datafrom 134 hospitals." 36 : 19-30, 2004